Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001737287-24-000079
Filing Date
2024-12-09
Accepted
2024-12-09 16:05:52
Documents
3
Period of Report
2024-12-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1733778343.html 4  
1 FORM 4 wk-form4_1733778343.xml 4 3524
2 EX-24 fhumer-allogenexsection1.htm EX-24 3786
3 fhumer-allogenexsection1001.jpg GRAPHIC 220936
  Complete submission text file 0001737287-24-000079.txt   313084
Mailing Address 388 GREENWICH STREET, 17TH FLOOR NEW YORK NY 10013
Business Address
Humer Franz B (Reporting) CIK: 0001548072 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 241535127

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)